Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response
William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward
William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward
View: Text | PDF
Research Article Immunology Oncology

The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response

  • Text
  • PDF
Abstract

Cyclic GMP-AMP synthase (cGAS) is a DNA sensor and responsible for inducing an antitumor immune response. Recent studies reveal that cGAS is frequently inhibited in cancer, and therapeutic targets to promote antitumor cGAS function remain elusive. SRC is a proto-oncogene tyrosine kinase and is expressed at elevated levels in numerous cancers. Here, we demonstrate that SRC expression in primary and metastatic bladder cancer negatively correlates with innate immune gene expression and immune cell infiltration. We determine that SRC restricts cGAS signaling in human cell lines through SRC small molecule inhibitors, depletion, and overexpression. cGAS and SRC interact in cells and in vitro, while SRC directly inhibits cGAS enzymatic activity and DNA binding in a kinase-dependent manner. SRC phosphorylates cGAS, and inhibition of cGAS Y248 phosphorylation partially reduces SRC inhibition. Collectively, our study demonstrates that cGAS antitumor signaling is hindered by the proto-oncogene SRC and describes how cancer-associated proteins can regulate the innate immune system.

Authors

William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward

×

Figure 6

cGAS is phosphorylated by SRC, and cGAS Y248 is partially responsible for SRC-mediated inhibition.

Options: View larger image (or click on image) Download as PowerPoint
cGAS is phosphorylated by SRC, and cGAS Y248 is partially responsible fo...
(A) In vitro kinase assay of 10 μM HA-SRC with various concentrations of FLAG-cGAS. Phosphorylation was analyzed by phosphor imaging. (B) In vitro kinase assay similar to A of 160 nM FLAG-cGAS with various concentrations of HA-SRC. (C) In vitro kinase assay similar to A of 160 nM FLAG-cGAS with 10 μM of WT and mutant HA-SRC. (D) Western blot of HEK293T cells transfected with FLAG-cGAS pcDNA3 and various SRC-HA pcDNA3 mutants for 24 hours, followed by FLAG IP and analysis of cGAS tyrosine phosphorylation. (E) Western blot similar to D with HEK293T cells treated with 30 nM dasatinib for 48 hours, followed by FLAG IP. Arrows depict nonspecific bands. (F) Schematic of human cGAS domains and observed tyrosine (Y) phosphorylation in PhosphoSitePlus. (G) Human cGAS structure (PDB ID: 4O67) with 2’3’ cGAMP in active site. Y248 is highlighted in red. (H) Western blot of HEK293T cells transfected with EV, WT, or Y248E/F FLAG-cGAS pcDNA3 mutants with or without SRC-HA pcDNA3 for 24 hours. (I) Coculture of L929-ISRE-LUC cells with cells in G (n = 4). Actin was used as a Western blot loading control. Statistical significance test: 1-way ANOVA with Tukey test (I). Representative assays shown. n = 3 (I).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts